Revolution advances daraxonrasib to Phase III in pancreatic cancer

Revolution Medicines (Nasdaq: RVMD) said Tuesday that it is advancing daraxonrasib into Phase III testing for pancreatic ductal adenocarcinoma after fresh data from its early-stage trials showed notable activity. New findings, presented to investors, covered long-term follow-up in previously treated patients and first results in the front-line setting.

The company reported that in second-line metastatic patients, daraxonrasib achieved response rates of 29%–35% depending on mutation type, with median overall survival reaching 13–15 months. In treatment-naïve patients, monotherapy produced a 47% response rate and 89% disease control. A chemotherapy combination pushed the response rate to 55%. Both regimens showed a manageable safety profile.

The biotech will complete enrollment this year for its ongoing RASolute 302 trial, assessing daraxonrasib in relapsed disease, with results due in 2026. A second study, RASolute 303, is scheduled to launch later this year in newly diagnosed patients, comparing monotherapy and a chemo-combination against standard care.